{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:00:03Z","timestamp":1787162403684,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ijid.2024.01.001","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T10:31:19Z","timestamp":1704277879000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment"],"prefix":"10.1016","volume":"140","author":[{"given":"Sainan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Davies","family":"Forsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5290-5165","authenticated-orcid":false,"given":"Katarina","family":"Niward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bruchfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2024.01.001_bib0001","unstructured":"World Health Organization; Global tuberculosis report 2022. Geneva: 2022."},{"issue":"6","key":"10.1016\/j.ijid.2024.01.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report","volume":"54","author":"Borisov","year":"2019","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ijid.2024.01.001_bib0003","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.ijid.2024.01.001_bib0004","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/cpt.2685","article-title":"Assessing prolongation of the corrected QT interval with bedaquiline and delamanid coadministration to predict the cardiac safety of simplified dosing regimens","volume":"112","author":"Tanneau","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ijid.2024.01.001_bib0005","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jac\/dkac019","article-title":"Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study","volume":"77","author":"Wasserman","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.ijid.2024.01.001_bib0006","doi-asserted-by":"crossref","first-page":"ofab660","DOI":"10.1093\/ofid\/ofab660","article-title":"Model-based efficacy and toxicity comparisons of moxifloxacin for multidrug-resistant tuberculosis","volume":"9","author":"Yun","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2024.01.001_bib0007","series-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","year":"2019"},{"issue":"3","key":"10.1016\/j.ijid.2024.01.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01925-2021","article-title":"Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China","volume":"59","author":"Zheng","year":"2022","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ijid.2024.01.001_bib0009","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5588\/ijtld.22.0188","article-title":"Clinical standards for the dosing and management of TB drugs","volume":"26","author":"Alffenaar","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"10.1016\/j.ijid.2024.01.001_bib0010","first-page":"859","article-title":"Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition)","volume":"43","year":"2021","journal-title":"Chinese J. Antituberculosis"},{"key":"10.1016\/j.ijid.2024.01.001_bib0011","unstructured":"National Cancer Institute; National Cancer Institute; National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events. U.S. Department of Health & Human Services (HHS); 2017. v5.0. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"10.1016\/j.ijid.2024.01.001_bib0012","series-title":"Active tuberculosis drug-safety monitoring and management (aDSM): framework for implementation","year":"2015"},{"issue":"8","key":"10.1016\/j.ijid.2024.01.001_bib0013","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.ijid.2024.01.001_bib0014","doi-asserted-by":"crossref","first-page":"e00419","DOI":"10.1128\/AAC.00463-19","article-title":"Daily dosing for bedaquiline in patients with tuberculosis","volume":"63","author":"Salinger","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2024.01.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122397","article-title":"Development and validation of a simple LC-MS\/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma","volume":"1158","author":"Zheng","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"11","key":"10.1016\/j.ijid.2024.01.001_bib0016","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.ijid.2024.01.001_bib0029","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3109\/00365548.2013.826876","article-title":"TBscore II: refining and validating a simple clinical score for treatment monitoring of patients with pulmonary tuberculosis","volume":"45","author":"Rudolf","year":"2013","journal-title":"Scand J Infect Dis"},{"issue":"5","key":"10.1016\/j.ijid.2024.01.001_bib0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5603\/ARM.2018.0032","article-title":"Chest X ray score (Timika score): an useful adjunct to predict treatment outcome in tuberculosis","volume":"86","author":"Chakraborthy","year":"2018","journal-title":"Adv Respir Med"},{"key":"10.1016\/j.ijid.2024.01.001_bib0017","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijid.2021.07.038","article-title":"Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis","volume":"110","author":"Li","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"11","key":"10.1016\/j.ijid.2024.01.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02399-20","article-title":"Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant tuberculosis","volume":"65","author":"Ngwalero","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ijid.2024.01.001_bib0019","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/psp4.12722","article-title":"Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis","volume":"10","author":"Tanneau","year":"2021","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.ijid.2024.01.001_bib0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"10.1016\/j.ijid.2024.01.001_bib0021","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1093\/cid\/ciac485","article-title":"Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment","volume":"76","author":"Eimer","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ijid.2024.01.001_bib0022","doi-asserted-by":"crossref","first-page":"e00019","DOI":"10.1128\/AAC.00055-19","article-title":"Cycloserine population pharmacokinetics and pharmacodynamics in patients with tuberculosis","volume":"63","author":"Alghamdi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2024.01.001_bib0023","doi-asserted-by":"crossref","first-page":"e00720","DOI":"10.1128\/AAC.00744-20","article-title":"Treatment outcomes and adverse drug effects of ethambutol, cycloserine, and terizidone for the treatment of multidrug-resistant tuberculosis in South Africa","volume":"65","author":"van der Walt","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2024.01.001_bib0024","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ijid.2021.03.001","article-title":"Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis","volume":"105","author":"Court","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.ijid.2024.01.001_bib0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40264-015-0267-y","article-title":"Safety and tolerability profile of second-line anti-tuberculosis medications","volume":"38","author":"Ramachandran","year":"2015","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.ijid.2024.01.001_bib0026","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-021-00997-0","article-title":"Population pharmacokinetics and bayesian dose adjustment to advance TDM of anti-TB drugs","volume":"60","author":"Sturkenboom","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.ijid.2024.01.001_bib0027","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.arbres.2016.10.021","article-title":"Diabetes is associated with severe adverse events in multidrug-resistant tuberculosis","volume":"53","author":"Mu\u00f1oz-Torrico","year":"2017","journal-title":"Arch Bronconeumol"},{"issue":"4","key":"10.1016\/j.ijid.2024.01.001_bib0028","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1128\/AAC.01866-12","article-title":"A novel mechanism underlies the hepatotoxicity of pyrazinamide","volume":"57","author":"Shih","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:12:47Z","timestamp":1761120767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971224000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":30,"alternative-id":["S1201971224000018"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2024.01.001","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2024.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}